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Abstract Subtypes of P2Y receptors are well characterized
with respect to their agonist profile but little is known about
differences in their intracellular signalling properties. When
expressed in Xenopus oocytes, both P2Y2 and P2Y6 receptors
effectively couple to endogenous Ca2+-dependent Cl3-channels.
However, only P2Y2 receptors increased currents mediated by
inward-rectifier K+ channels of the Kir3.0 subfamily. This
incrase in Kir-current was sensitive to pertussis toxin, while
activation of Ca2+-dependent Cl3-channels was not. In contrast,
suramin, a P2 receptor antagonist, inhibited activation of both
channels. These observations suggest that, in contrast to P2Y6,
P2Y2 receptors couple to two different classes of G proteins.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Receptors for extracellular nucleotides are widely expressed
and involved in a variety of cellular functions. Based on phar-
macological and structural properties, they have been subdi-
vided into P1 or adenosine receptors and P2 receptors which
are activated by nucleotide di- or triphosphates [1,2]. The P2
receptor family comprises both ionotropic receptors (P2X)
and metabotropic receptors (P2Y) from the superfamily of
G-protein-coupled receptors (GPCRs; [3,4]).
About 10 subtypes of P2Y receptors have been cloned from
several species [2]. Each P2Y receptor subtype has a distinct
pharmacological pro¢le de¢ned by its activation via ATP,
UTP and respective analogs [1]. Stimulation of intracellular
second messenger pathways by P2Y receptors is predomi-
nantly mediated by the GKq=11 subfamily of G-protein K-sub-
units [1] which activates phospholipase C (PLC) and subse-
quently stimulates inositol phosphates and 1,2-diacylglycerol
(DAG) leading to a rise in intracellular free Ca2 and activa-
tion of protein kinase C. All cloned P2Y receptor subtypes
activate this pathway. Work on P2Y receptors in various
types of cell and tissues, however, demonstrated quite a var-
iability in e¡ector types [5^10] as well as in G-protein K-sub-
units mediating this e¡ector-coupling [8,10^12]. Moreover, ex-
tracellularly applied ATP activated an inwardly-rectifying
potassium (K) current in atrial myocytes [12,13] in a pertus-
sis toxin sensitive manner. These cells are known to express
inward-recti¢er K (Kir) channels which are directly activated
by G-protein L/Q subunits [14].
On the other side, only limited information is available
from comparative studies that determine di¡erences in signal
transduction between recombinant P2Y receptor subtypes
[15^17]. Part of the P2Y2 and P2Y4 receptor mediated mobi-
lization of intracellular Ca2 was pertussis toxin sensitive
which indicates that these receptors may activate GKi=o pro-
teins [15,17]. However, only one report yet described activa-
tion of an GKi=o protein mediated e¡ect by a P2Y receptor
subtype, namely the pertussis toxin sensitive inhibition of
N-type Ca2 channels by P2Y2 receptors expressed in neuro-
nes [18].
To investigate the signal transduction properties of re-
combinant P2Y receptors, we expressed two mammalian re-
ceptor subtypes, P2Y2 and P2Y6, in Xenopus oocytes either
alone or in combination with G-protein-activated Kir chan-
nels (GIRK channels or Kir channels of the Kir3.0 subfam-
ily). This o¡ered the advantage to monitor two di¡erent ef-
fectors of G protein activity, the endogenous Ca2-activated
Cl3-channels [19,20] and the Kir channels directly sensitive to
activated GL/Q.
2. Materials and methods
2.1. Materials
Inorganic chemicals were from Fluka and Sigma (Buchs, Switzer-
land); HPLC-puri¢ed ATP and UTP from Pharmacia (Heidelberg,
Germany); UDP, suramin, the pertussis toxin holomer and hexoki-
nase from Sigma; 2-methylthio-ATP (2MeATP) from RBI (Natick,
MA, USA); the A protomer of pertussis toxin from Calbiochem (La
Jolla, CA, USA); in vitro cRNA transcription kit from Ambion (Aus-
tin, TX, USA); 3-aminobenzoic acid ethyl ester (MS222) for frog
anesthesia and collagenase from Sigma.
2.2. Expression of P2Y receptors and Kir3.0 potassium channels in
Xenopus oocytes
Plasmids for mouse P2Y2 (kind gift of D.J. Julius), human P2Y6
receptors [14] and rat Kir3.0 channels were linearized and transcribed
into capped cRNA using a cRNA transcription kit (Ambion, Hous-
ton, TX, USA). Stock solutions were prepared containing either all
subtypes (Kir3.1/2/3/4) or Kir3.1/2 at the same concentration ratio.
For oocyte preparation, female Xenopus laevis frogs (SNAKE, South
Africa) were anesthetized in 0.15% 3-aminobenzoic acid ethyl ester
and placed on ice during surgical removal of 4^5 lobes of oocytes.
Oocytes were kept in modi¢ed Barth’s solution (mBS; 88 mM NaCl,
1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 0.34 mM Ca(NO3)2,
0.41 mM CaCl2, 10 mM HEPES, pH 7.5) containing 100 U/ml pen-
icillin and streptomycin and prepared for injection in the following
way. Oocytes were mechanically isolated with forceps, incubated in
2 mg/ml collagenase (type IA) for 30 min at 37‡C, washed twice with
mBS, incubated in 4 mM EGTA (pH 8.5) for 4 min and slightly
agitated until the follicular membranes were removed. Treated oocytes
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were washed and placed in mBS at 18‡C for 6^20 h before injection.
P2Y and Kir encoding mRNA were mixed prior to injection at a ratio
of 1:1 (v/v) and a volume of about 50 nl was air-pressure injected into
each defolliculated stage V^VI oocyte using thin-wall borosilicate
capillaries with tip diameters of 15^30 Wm. mRNA concentrations
were adjusted to keep the stimulation of endogenous IClCa at a sub-
maximal level and to yield about the same current response for P2Y2
and P2Y6 receptors (see Fig. 3E,F). In some experiments, various
amounts of either P2Y receptor or Kir3.0 channel encoding mRNA
was injected to study coupling properties of P2Y receptors to Kir3.0
channels at various expression levels. After injection, oocytes were
placed for 3^6 days at 17‡C and mBS was changed every 72 h.
2.3. Electrophysiological measurement and analysis
For recording, oocytes were placed in a perfusion chamber (0.2 ml)
with continuous gravity £ow (2 ml/min) of normal frog Ringer (NFR)
containing 115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, 10 mM
HEPES, pH 7.2), or high-potassium frog Ringer (KFR) where
87.5 mM NaCl was replaced by KCl. Recording electrodes for two-
electrode voltage clamp contained 3 M KCl and had tip resistances of
0.7^2 M6. The following stock solutions were prepared: 100 mM
HPLC-puri¢ed ATP and UTP, 100 mM UDP, 50 mM suramin and
10 mM 2MeATP, all stored at 320‡C. Before use, UDP was treated
for at least 1 h at 10 mM ¢nal concentration with 50 U/ml hexokinase
and 100 mM glucose to remove contaminations of UTP. Pertussis
toxin holomer was dissolved in dH2O, added to the Barth’s medium
to give a ¢nal concentration of 1 Wg/ml and preincubated with the
oocytes for at least 40 h. The A-protomer of pertussis toxin was
dissolved in high ionic strength bu¡er at a concentration of 100 Wg/
ml and stored at +4‡C. For injection, the stock solution was dissolved
1:10 in H2O, and 50 nl/oocyte were injected 10^20 h prior to measure-
ment. A Geneclamp 500 ampli¢er was used together with a Digidata
1200 board and pClamp 6 (Axon Instruments, Foster City, CA, USA)
to digitize the current and voltage signals. Voltage ramps from 3100
to +50 mV in 2.5 s were used to estimate the current-voltage (I-V)
relation in the absence and presence of test compound. Current sig-
nals were low-pass ¢ltered (4-pole Bessel ¢lter) at 50 Hz and digitized
at 200 Hz for I-V and at 10 Hz for continuous sampling. Data were
analyzed using Igor Pro (Wavemetrics, Lake Oswego, OR, USA).
EC50 and IC50 values and their S.E.M. values were calculated from
their logarithms giving unsymmetrically linear S.E.M. values. Stu-
dent’s t-test was used to test for statistically signi¢cant di¡erences
between two data sets.
3. Results
We recently cloned the human P2Y6 receptor and studied
its expression pro¢le in a number of tissues and cell lines [21].
To elucidate possible di¡erences between P2Y6 and other P2
receptors, we ¢rst established the pharmacological pro¢le of
P2Y6 and P2Y2 heterologously expressed in Xenopus oocytes.
As shown in Fig. 1, both receptor subtypes were about
equally e¡ective in activating endogenous Ca2-dependent
Cl3-channels (IClCa ; [19]) in defolliculated oocytes (Fig.
1A,C; current-voltage relation (I-V) in Fig. 1B,D). The ago-
nist pro¢le, however, was rather di¡erent. Whereas P2Y6 re-
ceptors responded to UDP but not to 2MeATP, ATP or UTP,
P2Y2 receptors were stimulated by ATP and UTP, but not by
UDP or 2MeATP (the preferred agonist for P2Y1 receptors).
In both cases the current response was blocked by 50 WM
suramin, a non-speci¢c inhibitor of P2Y receptor subtypes.
The small Cl3-current observed upon wash-out of coapplied
agonists and suramin most likely re£ects residual nucleotides.
Since amplitude and time-course of the endogenous IClCa
varied signi¢cantly between individual oocytes, we coex-
pressed inward-recti¢er K channels of the Kir3.0 subfamily
for a more detailed study of the pharmacological properties
and the signalling pathways of our P2Y receptors. Kir3.0
channels, which deliver most robust currents when assembled
as heteromultimers, are well known to couple to many
GPCRs and to be activated by the L/Q complex of G proteins
[14].
Surprisingly, receptor-stimulated activation of currents
mediated by heteromultimeric Kir3.1/2 channels (IKir) was
only observed for P2Y2 receptors, while stimulation of P2Y6
did not a¡ect IKir. Fig. 2A and D show such experiments,
where currents of whole oocytes were recorded at a constant
membrane potential of 370 mV and agonist was applied in a
solution containing 90 mM K. The initial increase in inward
current (blocked by 1 mM BaCl2, not shown) seen in both
experiments results from the increase in extracellular K con-
centration. While activation of P2Y2 by ATP led to a stable
and more than two-fold increase in inward IKir (Fig. 2D),
stimulation of P2Y6 by UDP just led to the transient increase
in IClCa (Figs. 1 and 2A). The di¡erential e¡ect of both
receptors is more evidently illustrated in Fig. 2C and F which
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Fig. 1. Agonist pro¢le of recombinant P2Y6 and P2Y2 receptors ex-
pressed in Xenopus oocytes. A: Whole-cell current measured in re-
sponse to stimulation of human P2Y6 receptors by various nucleoti-
des at a concentration of 10 WM. Bath solution was NFR, holding
potential was 370 mV. Fifty WM suramin partially blocked IClCa
elicited by 10 WM UDP. B: I-V of Ca2-dependent Cl3-channels
measured in response to a voltage-ramp from 3100 to +50 mV
after activation of currents by 10 WM UDP. C: Experiment as in A
but with oocytes expressing mouse P2Y2 receptors. D: I-V as in B
measured after stimulation of P2Y2 receptors by 10 WM ATP.
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represent I-Vs obtained by subtracting the I-Vs recorded be-
fore and during stimulation of either receptor (Fig. 2B,E). For
P2Y6 the result was very similar to that obtained without
coexpressed Kir channels (Fig. 1BFig. 2C). The I-V resulting
from stimulation of P2Y2, however, clearly exhibited two
components: the Kir-mediated inward current seen at poten-
tials negative to about 330 mV and the outward-rectifying
IClCa (Fig. 2F). In addition, Fig. 2 shows that stimulation
of either receptor resulted in a slowly developing decrease of
the basal IKir (I-Vs at timepoints b and d in Fig. 2A,B and
D,E).
To determine whether the P2Y2 mediated increase in IKir
was agonist speci¢c, 10 WM UTP was applied instead of ATP.
UTP increased IKir to an extent similar to that observed
for ATP (Fig. 3). The average ratio of current in the presence
of agonist vs. baseline current (Iagonist/Icontrol) measured at
370 mV for P2Y2 receptors was 3.6 þ 0.6 (mean þ S.E.M.,
n = 9; Fig. 3A) and 3.8 þ 0.4 (n = 12) for ATP and UTP, re-
spectively. In contrast, little change in Iagonist/Icontrol was seen
for P2Y6 receptors stimulated by 10 WM UDP under identical
conditions (1.1 þ 0.04, n = 11; Fig. 3A). In the latter case, the
IClCa might account for the small upregulation seen with
P2Y6 receptors. At +50 mV, Iagonist/Icontrol was not signi¢-
cantly di¡erent for both receptors. The respective values
were 3.3 þ 0.3 (n = 10) for P2Y6 receptors and 6.5 þ 0.8
(n = 7) and 3.8 þ 0.4 (n = 8) for P2Y2 activated by 10 WM
ATP and 10 WM UTP, respectively (Fig. 3B). As shown later,
suramin was also able to block IKir activation by P2Y2 recep-
tors.
It might be that Kir3.0 subtypes are di¡erentially sensitive
to receptor stimulation. Therefore, all four Kir3.0 subunits
cloned to date (Kir3.1, 3.2, 3.3, 3.4) were coinjected with
P2Y6 or P2Y2 receptors. However, no di¡erences to experi-
ments with Kir3.1/2 heteromers were found. These results
clearly indicate that while both P2Y2 and P2Y6 receptors
e¡ectively activate Ca2-dependent Cl3-channels, it is only
P2Y2 that couples to coexpressed Kir channels.
Two possible explanations may exist for this di¡erential
coupling of P2Y2 receptors to IClCa and IKir : P2Y2 interacts
with one type of G protein that activates both e¡ectors, or
P2Y2 interacts with more types of G proteins that each acti-
vate a distinct e¡ector. In order to address this question,
oocytes expressing P2Y2 and Kir3.1/2/3/4 channels were incu-
bated for at least 48 h in 1 Wg/ml pertussis toxin or injected
with 50 nl of the A protomer of pertussis toxin (10 ng/Wl) 20 h
prior to electrophysiological recordings. As shown in Fig. 4,
in pertussis-toxin treated cells Kir channels did not respond to
receptor stimulation, whereas the increase in IClCa was vir-
tually left unchanged (Fig. 4A,B). Fig. 4C summarizes the
results obtained from 6 oocytes tested and compares the result
to untreated oocytes. This ¢nding favors the hypothesis that
P2Y2 activates at least two G proteins, a pertussis toxin-sen-
sitive G protein which couples the P2Y2 receptor to IKir and a
pertussis toxin-insensitive G protein which leads to stimula-
tion of IClCa.
The fast inactivation of IClCa and its desensitization upon
repetitive receptor stimulation (Fig. 5A,B) can mask a heter-
ologous desensitization of the receptor itself and makes it
di⁄cult to perform dose-response experiments. The upregula-
tion of IKir did not show a signi¢cant desensitization (Fig.
5A,B) indicating that the P2Y2 receptor does not desensitize
within the time course of the experiment (20 min). Therefore,
we used IKir to characterize the pharmacological properties of
P2Y2 receptors. The dose-response relationship for activation
of P2Y2 by ATP and UTP (Fig. 5C,E) showed that both
agonists are equally potent: EC50 values were 1.2+0.4/30.3
WM (n = 8) and 1.0 þ 0.1 WM (n = 5), with Hill coe⁄cients of
1.1 þ 0.2 and 1.3 þ 0.2 for ATP and UTP, respectively. Inhib-
ition of P2Y2 by suramin measured in cumulative experiments
in the presence of 10 WM ATP (Fig. 5D) resulted in a dose-
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Fig. 2. P2Y2 but not P2Y6 activate coexpressed Kir3.1/2 channels. A: Currents recorded at 370 mV evoked by application of 10 WM UDP to
oocytes coexpressing P2Y6 receptors and Kir3.1/2 channels. Increase in IKir observed upon switch from NFR to KFR is due to the shift in K
reversal potential. B: I-Vs measured as in Fig. 1 at the timepoints indicated in A. C: Agonist-induced current obtained by subtraction of the
I-Vs measured at c and b in B. D: Same experiment as in A but for P2Y2 receptors activated by 10 WM ATP. E, F: I-Vs and agonist-induced
current as in B and C but for P2Y2 receptors. Note in F that ATP activated both IClCa and IKir.
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response curve with an IC50 of 33+9/37 WM and a Hill co-
e⁄cient of 1.4 þ 0.4 (n = 5) (Fig. 5F).
4. Discussion
The initial goal of this study was a pharmacological and
functional comparison of two P2Y receptors, P2Y2 and P2Y6.
We used the Xenopus oocyte expression system with two ion
channels as e¡ector systems, the Ca2-activated Cl3-channel
endogenous to the oocytes, and coexpressed Kir3.0 channels
which are directly activated by GPCRs via the L/Q complex of
G proteins.
The observation that both P2Y2 and P2Y6 receptors acti-
vate IClCa in the oocyte indicates that P2Y2 and P2Y6 both
activate PLC [4,22]. In support of this, stimulation of both
receptor subtypes induced a slow downmodulation of IKir
which was shown to be mediated by protein kinase C depend-
ent phosphorylation of the Kir3.0 channels [23].
However, we found that only P2Y2 receptors are able to
activate IKir even though the stimulation of IClCa was com-
parable between P2Y2 and P2Y6 expressing oocytes. This may
imply that both subtypes couple to di¡erent intracellular sig-
nalling pathways. It was suggested that some P2Y receptors
induce a rise in intracellular free Ca2 via the L/Q complex of a
GKi=o protein [8,10,24]. Therefore, we tried to block the P2Y2
receptor mediated responses by pertussis toxin. Surprisingly,
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Fig. 3. Histograms illustrating the average e¡ect of P2Y receptors on IClCa and IKir. A: Average ratio of currents in the presence and absence
of agonist (timepoint c and b in Fig. 2) measured at a potential of 370 mV. B: Ratio as in A for currents measured at +50 mV. Data are tak-
en from I-V experiments as shown in Fig. 2B and E. C, D: Average recti¢cation indices of agonist-induced currents (timepoints c^b in Fig. 2)
in NFR (C) and KFR (D). A ratio of 1 indicates a linear I-V, values 6 1 indicate an outwardly-rectifying I-V. Error bars are S.E.M., number
of cells tested is indicated. E, F: Upregulation of currents at 370 mV vs. current amplitudes in the presence of an agonist at +50 mV (E) and
basal current at 370 mV (F) in KFR shown for single cells. Filled symbols show data for P2Y2, open symbols for P2Y6 receptors. Triangles
represent data taken from oocytes injected with 10 times (P2Y2) or 5 times (P2Y6) higher amount of mRNA. Experiments shown in this ¢gure
are from at least 3 batches of oocytes, data from cells either coexpressing Kir3.1/2 or Kir3.1/2/3/4 channels are pooled.
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only the coupling to the Kir3.0 channels was disrupted in
pertussis toxin treated cells while the stimulation of IClCa
was almost una¡ected. In parallel, the stimulation of IClCa
by P2Y6 receptors remained unaltered upon treatment with
pertussis toxin. These results strongly suggest that P2Y2 re-
ceptors are multifunctional GPCRs activating two di¡erent G
proteins from the GKi=o and GKq=11 families whereas P2Y6
receptors only activate GKq=11 proteins. This ¢nding on re-
combinant P2Y receptors is in agreement with reports show-
ing a pertussis toxin sensitive coupling of native P2Y receptors
in atrial myocytes to inward potassium channels [12,13] and
to Ca2 channels in chroma⁄n cells [5], as well as with ¢nd-
ings that aortic endothelial cells respond to application of
UTP in a pertussis toxin sensitive manner [24].
It remains unclear why P2Y6 receptors unlike many other
GPCRs do not couple to Kir channels. Almost all of the
coexpression studies with Kir3.0 channels were done with
GPCRs coupling to GKi=o and GKs proteins. Thus, it is pos-
sible that the number of GL/Q complexes activated by a re-
ceptor coupling to GKq=11 is too low to allow a signi¢cant
upregulation of the Kir3.0 channels. Di¡erences in expression
level of G proteins or in their GTPase activity might account
for this e¡ect. Alternatively, the L/Q complex of GKq=11 pro-
teins may di¡er from the L/Q complex associated with GKi=o
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Fig. 4. Pertussis toxin selectively abolished coupling of P2Y2 receptors to Kir3.0 channels. A: I-V recordings from oocytes coexpressing P2Y2
receptors and Kir3.1/2/3/4 channels. Experimental conditions as in Fig. 2. B: I-Vs from oocytes incubated in 10 ng/Wl pertussis toxin for 48 h
prior to recordings. Experimental conditions as in Fig. 2. C: Average e¡ect of pertussis toxin treatment (n=6). Controls and pertussis toxin
treated oocytes were from the same two batches of oocytes. Star indicates statistically signi¢cant reduction of the agonist-induced current at
370 mV in pertussis toxin-treated cells vs. controls (*P6 0.05, Student’s t-test).
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proteins and only the latter types can activate the Kir3.0
channels. Third, the P2Y6 receptor and the G protein might
not form a functional complex with the Kir channels which
seems to be necessary for the membrane-delimited GL/Q sig-
nalling [14]. There is at least one case where GKq=11 coupled
receptors activate coexpressed Kir3.0 channels [25]. However,
it was speculated that this coupling of an mGluR1 receptor
arose from promiscuous coupling of overexpressed receptor
proteins to GKi=o or GKs because the same experiment could
not be repeated with lower expression levels in the same ex-
pression system [23]. A dependence of the coupling pathway
on the expression level was also found for other receptors [22].
In our case, we do not assume that overexpression of the
P2Y2 receptor explains the di¡erential behavior of the P2Y
subtypes since the stimulated IClCa is comparable and at a
submaximal level for both P2Y receptors tested. Taking the
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Fig. 5. Dose response relationship of P2Y2 receptors for ATP, UTP and for suramin as obtained from activation and inhibition of IKir.
A: Current response of oocytes coexpressing P2Y2 receptors and Kir3.1/2 on repetitive application of ATP. While the peak amplitude of IClCa
desensitizes after the ¢rst application, upregulation of IKir remains almost unaltered upon the second application. B: Time course of current
amplitudes measured at 370 mV from consecutive voltage ramps in the presence (IKir(10 WM ATP)) and absence (basal IKir) of agonist in high
K. C: I-Vs recorded at di¡erent concentrations of UTP; leak current was not subtracted. D: Concentration-response curves for ATP (open
circles) and UTP (¢lled circles). Agonist-induced current amplitudes at 370 mV from di¡erent oocytes were normalized to the value measured
at 10 WM agonist concentration. Error bars are S.E.M. from at least 8 independent experiments. Lines represent ¢ts of a Hill equation to the
data points. E: IKir in KFR activated by 10 WM ATP were inhibited by increasing concentrations of coapplied suramin. Bars show application
of indicated concentrations of suramin in WM. F: Dose-response relation for suramin on P2Y2 receptors obtained from 5 experiments as in E.
Steady-state currents were normalized to their amplitude in 10 WM ATP and 0 WM suramin. Line represents ¢tted Hill equation.
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stimulated IClCa as a measure of P2Y receptor expression, we
did not ¢nd any correlation between expression level and IKir
upregulation (Fig. 3E,F).
There are several examples of GPCRs which couple to two
G proteins of di¡erent families [22,26]. D2 dopamine recep-
tors, thrombin receptors and 5-HT 1a receptors couple both
negatively to adenylyl cyclase and stimulatory to PLC [27^29].
The properties of the P2Y2 receptor are similar to those
GPCRs as one pathway is pertussis toxin sensitive and the
other induces a rise in intracellular Ca2. In the case of the
thrombin receptor, it could also be shown that the stimulation
of inositol phosphates was not blocked by treatment with
pertussis toxin [29] similar to our study.
It might be questioned whether the bifunctional behavior of
P2Y2 receptors that we have found is speci¢c for our expres-
sion system. However, several studies have found activation of
PLC and inhibition of adenylyl cyclase by native P2Y1- and
P2Y2-like receptors in di¡erent cell types [4,10,24]. In addi-
tion, Communi et al. [16] recently cloned a P2Y receptor
which stimulates adenylyl cyclase and PLC when expressed
in CHO K1 and 1321N1 astrocytoma cells, respectively.
This suggests that P2Y2 receptors expressed in oocytes as in
other systems are able to activate multiple second messenger
pathways.
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